IMTX

BEARISH

$10.43 Live

Immatics N.V. · NASDAQ

Target $18.75 (+79.8%)

$3.94 52W Range $12.41

IMTX Immatics N.V. - Fundamental Analysis

BEARISH

Console Chart News

IMTX Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$10.43

Analyst Target

$18.75

+79.8% Upside

52W High

$12.41

52W Low

$3.94

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 12, 2026

Market cap

$1.4B

P/E

N/A

ROE

-37.1%

Profit margin

N/A

Debt/Equity

0.03

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.

Key Strengths

Exceptional short-term liquidity with a Current Ratio of 11.72

Very low leverage with a Debt/Equity ratio of 0.03

Significant analyst price target upside (Target: $18.75 vs Price: $10.43)

Strong 1-year price appreciation (+162.7%)

High Quick Ratio (11.07) ensuring immediate obligations can be met

Key Risks

Severe revenue contraction (-64.90% YoY)

Extreme operational inefficiency with Gross Margins at -280.87%

Critical Piotroski F-Score (1/9) signaling fundamental decay

Highly inflated valuation relative to sales (P/S of 28.98)

Consistent failure to meet earnings estimates (1/4 beats in last 4 quarters)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative High-Risk

Key drivers: Revenue collapse, Negative margins, Extreme P/S ratio, Strong cash runway

Confidence

90%

Value

10/100

Ref P/S 28.98, Forward P/E -5.91

Positives

No standout positives identified.

Watchpoints

P/S ratio of 28.98 is unsustainable for shrinking revenue
No Graham Number available due to lack of earnings

Future

15/100

Ref Growth rates

Positives

Analyst target price suggests pipeline potential

Watchpoints

YoY Revenue Growth -64.90%
Q/Q Revenue Growth -64.87%

Past

30/100

Ref Historical trends

Positives

Strong 1Y price recovery

Watchpoints

Volatile earnings history
Consistent EPS misses

Health

40/100

Ref Piotroski F-Score

Positives

Very low Debt/Equity
High Current Ratio

Watchpoints

Piotroski F-Score 1/9
Negative ROE/ROA

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$10.43

Analyst Target

$18.75

Upside/Downside

+79.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for IMTX and closest competitors.

Updated 2026-04-10

Company	5Y	3Y	1Y	6M	1M	1W
IMTX Immatics N.V. Primary	-10.0%	+69.3%	+162.7%	+0.7%	+4.0%	+0.8%
ARDX Ardelyx, Inc. Peer	-17.1%	+46.3%	+6.6%	-12.6%	-20.4%	-6.6%
HCSG Healthcare Services Group, Inc. Peer	-26.4%	+29.9%	+99.3%	+28.4%	-2.7%	+6.2%
BCRX BioCryst Pharmaceuticals, Inc. Peer	-25.9%	-38.3%	-12.2%	-20.6%	-11.8%	+1.9%
AHCO AdaptHealth Corp. Peer	-72.3%	-20.2%	+10.2%	+14.1%	+0.5%	+11.6%

IMT

Immatics N.V.

Primary

-10.0%

+69.3%

+162.7%

+0.7%

+4.0%

+0.8%

ARD

Ardelyx, Inc.

Peer

-17.1%

+46.3%

+6.6%

-12.6%

-20.4%

-6.6%

HCS

Healthcare Services Group, Inc.

Peer

-26.4%

+29.9%

+99.3%

+28.4%

-2.7%

+6.2%

BCR

BioCryst Pharmaceuticals, Inc.

Peer

-25.9%

-38.3%

-12.2%

-20.6%

-11.8%

+1.9%

AHC

AdaptHealth Corp.

Peer

-72.3%

-20.2%

+10.2%

+14.1%

+0.5%

+11.6%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-5.91

N/A

2.5

28.98

19.58

-5.47

$1.4B

Profitability

Profit margins and return metrics

Profit Margin N/A

Operating Margin -196.76%

Gross Margin -280.87%

ROE -37.1%

ROA -18.08%

Growth

Revenue and earnings growth rates

Revenue Growth -64.9%

Earnings Growth N/A

Q/Q Revenue Growth -64.87%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.03

Low debt

Current Ratio

11.72

Strong

Quick Ratio

11.07

Excellent

Cash/Share

$3.5

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Op. Margin

-196.8%

Net Margin

-180.6%

Total Assets

$0.6B

Liabilities

$0.1B

Equity

$0.5B

Debt/Equity

0.16x

Operating CF

$-0.1B

CapEx

$-0.0B

Free Cash Flow

$-0.1B

FCF Yield

102%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-06

$N/A

2026-03-05

$-0.34

+29.2% surprise

2025-11-17

$-0.49

-7.4% surprise

2025-08-13

$-0.68

-88.3% surprise

Healthcare Sector Comparison

Comparing IMTX against 264 companies in the Healthcare sector (20 bullish, 87 neutral, 157 bearish)

Return on Equity (ROE)

-37.1%

This Stock

-46.09%

Sector Avg

-19.5% (Below Avg)

Debt to Equity

0.03

This Stock

4.1

Sector Avg

-99.2% (Less Debt)

Revenue Growth

-64.9%

This Stock

88.16%

Sector Avg

-173.6% (Slower)

Current Ratio

11.72

This Stock

3.58

Sector Avg

+227.5% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
IMTX Immatics N.V.	BEARISH	$1.4B	-	-37.1%	-%	$10.43
ARDX Ardelyx, Inc.	NEUTRAL	$1.42B	-	-36.2%	-15.1%	$5.78	Compare
HCSG Healthcare Services Group, Inc.	BULLISH	$1.37B	24.06	11.7%	3.2%	$19.49	Compare
BCRX BioCryst Pharmaceuticals, Inc.	NEUTRAL	$1.43B	-	-%	-1.5%	$6.79	Compare
AHCO AdaptHealth Corp.	BEARISH	$1.44B	-	-4.3%	-2.2%	$10.6	Compare

IMTX Immatics N.V.

BEARISH

Mkt Cap

$1.4B

P/E

ROE

-37.1%

Price

$10.43

Compare with IMTX

Compare with IMTX

Compare with IMTX

AHCO AdaptHealth Corp.

Compare with IMTX

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

8 analysts

Chardan Capital

2025-11-24

Maintains

Buy Buy

Mizuho

2025-11-19

Maintains

Outperform Outperform

Guggenheim

2025-11-18

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning IMTX from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

IMTX

IMTX Immatics N.V. - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!